IP Library Granted Patent US 7,189,707
Granted Patent B2
US 7,189,707 · App. 10/349,171 · Granted Mar 13, 2007

Substituted porphyrins

Assignees: National Jewish Medical Research Center; Duke University; Aeolus Sciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,189,707
App. No.
10/349,171
Granted
Mar 13, 2007
Kind
B2
Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims (23)

1. A method of protecting cells from oxidant-induced toxicity comprising contacting said cells with an effective amount of a compound of formula

or pharmaceutically acceptable salt thereof,

wherein

R 1 and R 3 are the same and are:

R 2 and R 4 are the same and are:

Y is halogen or —CO 2 X, and

X is the same or different and is an alkyl and each R 5 is the same or different and is H or alkyl,

so that said protection is effected.

2. The method according to claim 1 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

3. The method according to claim 2 wherein said metal is manganese.

4. The method according to claim 1 wherein said cells are mammalian cells.

5. The method according to claim 4 wherein said cells are cells of an isolated organ.

6. The method according to claim 4 wherein said cells are cells of an organ transplant.

7. A method of treating a patient suffering from a condition that results from or that is exacerbated by oxidant-induced toxicity comprising administering to said patient an effective amount of a compound of formula

or pharmaceutically acceptable salt thereof,

wherein

R 1 and R 3 are the same and are:

R 2 and R 4 are the same and are:

Y is halogen or —CO 2 X, and

X is the same or different and is an alkyl and each R 5 is the same or different and is H or alkyl,

so that said treatment is effected.

8. The method according to claim 7 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

9. The method according to claim 8 wherein said compound is complexed with manganese.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2011
From: CRAPO, JAMES D.; DAY, BRIAN J.
To: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
Reel/Frame 026745/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2011
From: FRIDOVICH, IRWIN; BATINIC-HABERLE, INES
To: DUKE UNIVERSITY
Reel/Frame 026745/0337 →
CHANGE OF NAME Recorded Aug 12, 2011
From: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
To: NATIONAL JEWISH HEALTH
Reel/Frame 026746/0340 →
CONFIRMATORY LICENSE Recorded Jun 25, 2008
From: NATIONAL JEWISH CTR FOR IMMNLGY/RESP M
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021146/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2007
From: TROVA, MICHAEL P.; GAUUAN, POLIVINA J.; KITCHEN, DOUGLAS B.
To: AEOLUS PHARMACEUTICALS, INC.
Reel/Frame 019658/0290 →
CHANGE OF NAME Recorded Aug 7, 2007
From: AEOLUS PHARMACEUTICALS, INC.
To: AEOLUS SCIENCES, INC.
Reel/Frame 019658/0294 →
Continuity (3)
Continuation 0949053700 · Jan 25, 2000
Provisional Application 6011701000 · Jan 25, 1999
Related Publication 20040023941A1 · Feb 5, 2004